Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: Results of the INDEX trial

Headache

Volumn 45, Issue 1, 2005, Pages 17-24

  Dowson, Andrew J ^a   Charlesworth, Bruce R ^b,h   Green, Judy ^c   Färkkilä, Markus ^d   Diener, Hans Christoph ^e   Hansen, Steen Boes ^f   Gawel, Marek ^g  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c St Augustine's Hospital   (South Africa)

^d Helsinki Headache Centre   (Finland)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Kronobergskliniken   (Sweden)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^h PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Efficacy; Long term; Migraine; Nasal spray; Tolerability; Zolmitriptan

Indexed keywords

ZOLMITRIPTAN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE AURA; MULTICENTER STUDY; NASAL SPRAY; NASOPHARYNGEAL ADVERSE EVENT; NEBULIZATION; OPEN STUDY; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; AGED; HUMANS; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 11844270394     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05005.x     Document Type: Article

References (21)

1. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
2. Breslau N, Rasmussen BK. The impact of migraine. Epidemiology, risk factors, and co-morbidities. Neurology. 2001;56:45.
3. Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population. The GEM study. Neurology. 2000;55:624-629.
4. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology. 2000;55:S29-S35.
5. Lipton RB, Stewart WF, Reed M, et al. Migraine's impact today. Burden of illness, patterns of care. Postgrad Med. 2001;109:38-45.
6. Martin GR, Robertson AD, MacLennan SJ, et al. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol. 1997;121:157-164.
7. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain. 1996;67:355-359.
8. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache. 1994;34:394-399.
9. 1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol. 1998;5:535-543.
10. Rapoport AM, Ramadan NM, Adelman JU, et al., on behalf of The 017 Clinical Trial Study Group. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology. 1997;49:1210-1218.
11. Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology. 1997;49:1219-1225.
12. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache. 1998;38:173-183.
13. Volans GN. Migraine and drug absorption. Clin Pharmacokinet. 1978;3:313-318.
14. Charlesworth BR, Dowson AJ, Purdy A, et al. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine. CNS Drugs. 2003;17:653-667.
15. Yates R, Nairn K, Dixon R, et al. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. J Clin Pharmacol. 2002;42:1237-1243.
16. Yates RA, Sorensen J, Bergstrom M, et al. Distribution and pharmacokinetics of zolmitriptan following administration by nasal spray. Cephalalgia. 2001;21:417.
17. Dowson AJ, Charlesworth BR, Purdy A, et al. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs. 2003;17:839-851.
18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(Suppl 7):1-96.
19. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-926.
20. Klapper J, Lucas C, Røsjø Ø, et al. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004;24:918-924.
21. Dahlöf C. Integrating the triptans into clinical practice. Curr Opin Neurol. 2002;15:317-322.